David O Francis1,2, Kelly Williamson3, Kristen Hovis3, Alexander Gelbard1, Albert L Merati4, David F Penson2,5,6, James L Netterville1, C Gaelyn Garrett1. 1. Department of Otolaryngology, Vanderbilt Voice Center, Vanderbilt University Medical Center, Nashville, Tennessee, U.S.A. 2. Center for Surgical Quality and Outcomes Research, Institute for Medicine and Public Health, Vanderbilt University Medical Center, Nashville, Tennessee, U.S.A. 3. Vanderbilt University School of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, U.S.A. 4. Division of Laryngology, Department of Otolaryngology-Head & Neck Surgery, University of Washington, Seattle, Washington, U.S.A. 5. Department of Urological Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, U.S.A. 6. Geriatric Research Education and Clinical Center, Veterans Administration Tennessee Valley Healthcare System, Nashville, Tennessee, U.S.A.
Abstract
OBJECTIVES/HYPOTHESIS: To determine whether injection augmentation reduces the likelihood of ultimately needing definitive framework surgery in unilateral vocal fold paralysis (UVFP) patients. STUDY DESIGN: Retrospective cohort study. METHODS: All patients diagnosed with UVFP (2008-2012) at the academic center were identified. The time from symptom onset to presentation to either community otolaryngologist and/or academic center, as well as any directed treatment(s), were recorded. Stepwise, multivariate logistic regression analysis was used to determine whether injection augmentation independently affected odds of needing definitive, framework surgery among patients who were seen within 9 months of symptom onset and had not undergone any prior rehabilitative procedures. RESULTS: Cohort consisted of 633 patients (55% female, 80% Caucasian, median age 60 years) with UVFP. The majority of etiologies were either surgery (48%) or idiopathic (37%). Duration to presentation at community otolaryngologist was shorter than to the academic center (median 2 vs. 6 months). Overall, less than half of UVFP patients had any operation (46%). Multivariate logistic regression found that earlier injection augmentation did not affect odds of ultimately undergoing framework surgery (odds ratio 1.13; confidence interval, 0.92-1.40; P = 0.23). CONCLUSION: Nearly half of UVFP patients do not require any rehabilitative procedure. When indicated, early injection augmentation is effective at temporarily alleviating associated symptoms but does not reduce likelihood of needing a definitive framework operation in patients with UVFP. Understanding practice patterns and fostering early detection and treatment may improve quality of life in this patient population.
OBJECTIVES/HYPOTHESIS: To determine whether injection augmentation reduces the likelihood of ultimately needing definitive framework surgery in unilateral vocal fold paralysis (UVFP) patients. STUDY DESIGN: Retrospective cohort study. METHODS: All patients diagnosed with UVFP (2008-2012) at the academic center were identified. The time from symptom onset to presentation to either community otolaryngologist and/or academic center, as well as any directed treatment(s), were recorded. Stepwise, multivariate logistic regression analysis was used to determine whether injection augmentation independently affected odds of needing definitive, framework surgery among patients who were seen within 9 months of symptom onset and had not undergone any prior rehabilitative procedures. RESULTS: Cohort consisted of 633 patients (55% female, 80% Caucasian, median age 60 years) with UVFP. The majority of etiologies were either surgery (48%) or idiopathic (37%). Duration to presentation at community otolaryngologist was shorter than to the academic center (median 2 vs. 6 months). Overall, less than half of UVFP patients had any operation (46%). Multivariate logistic regression found that earlier injection augmentation did not affect odds of ultimately undergoing framework surgery (odds ratio 1.13; confidence interval, 0.92-1.40; P = 0.23). CONCLUSION: Nearly half of UVFP patients do not require any rehabilitative procedure. When indicated, early injection augmentation is effective at temporarily alleviating associated symptoms but does not reduce likelihood of needing a definitive framework operation in patients with UVFP. Understanding practice patterns and fostering early detection and treatment may improve quality of life in this patient population.
Keywords:
Unilateral vocal fold paralysis; framework surgery; injection augmentation; injection laryngoplasty; selection bias; time to presentation; type I laryngoplasty
Authors: A Bergenfelz; S Jansson; A Kristoffersson; H Mårtensson; E Reihnér; G Wallin; I Lausen Journal: Langenbecks Arch Surg Date: 2008-07-17 Impact factor: 3.445
Authors: Satyajit Marawar; Federico P Girardi; Andrew A Sama; Yan Ma; Licia K Gaber-Baylis; Melanie C Besculides; Stavros G Memtsoudis Journal: Spine (Phila Pa 1976) Date: 2010-07-01 Impact factor: 3.468
Authors: Sujana S Chandrasekhar; Gregory W Randolph; Michael D Seidman; Richard M Rosenfeld; Peter Angelos; Julie Barkmeier-Kraemer; Michael S Benninger; Joel H Blumin; Gregory Dennis; John Hanks; Megan R Haymart; Richard T Kloos; Brenda Seals; Jerry M Schreibstein; Mack A Thomas; Carolyn Waddington; Barbara Warren; Peter J Robertson Journal: Otolaryngol Head Neck Surg Date: 2013-06 Impact factor: 3.497
Authors: David O Francis; Ariel E Sherman; Kristen L Hovis; Kemberlee Bonnet; David Schlundt; C Gaelyn Garrett; Louise Davies Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-05-01 Impact factor: 6.223
Authors: Heidi Kletzien; Cameron L Macdonald; Jason Orne; David O Francis; Glen Leverson; Elizabeth Wendt; Rebecca S Sippel; Nadine P Connor Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-11-01 Impact factor: 6.223
Authors: Sara Fernandes-Taylor; Cara Damico Smith; Natalia Arroyo; Kemberlee Bonnet; David Schlundt; Margarete Wichmann; Irene Feurer; David O Francis Journal: BMJ Open Date: 2019-10-30 Impact factor: 2.692